Skip to main content

Acalabrutinib (ACP-196): A selective second-generation BTK inhibitor

129Citations
Citations of this article
156Readers
Mendeley users who have this article in their library.

This artice is free to access.

Abstract

More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. More selective BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored. Acalabrutinib (ACP-196) is a novel irreversible second-generation BTK inhibitor that was shown to be more potent and selective than ibrutinib. This review summarized the preclinical research and clinical data of acalabrutinib.

Cite

CITATION STYLE

APA

Wu, J., Zhang, M., & Liu, D. (2016, March 9). Acalabrutinib (ACP-196): A selective second-generation BTK inhibitor. Journal of Hematology and Oncology. BioMed Central Ltd. https://doi.org/10.1186/s13045-016-0250-9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free